John F Seymour
机构: Professor of Medicine, Director Dept of Haematology Peter MacCallum Cancer Centre & Royal Melbourne
主页: petermac.org
每年引用次数
引用次数
引用: 66,887
H-指数: 121
I10-指数 : 515
出版物: 1,147
Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).
Ulrich Germing , Michael Lauseker , Barbara Hildebrandt , Argiris Symeonidis
Blood 114 ( 22) 945 -945
11
2009
Therapeutic role of rituximab in the treatment of intravascular lymphoma
Gp Dognini , A Szomor , B Horvath , O Bairey
HAEMATOLOGICA 92 266 -267
2007
Clinical presentation, management and prognosis of angiotropic lymphoma in western countries: The IELSG experience on 37 HIV-negative cases.
Ajm Ferreri , E Campo , Jf Seymour , A Ambrosetti
BLOOD 102 ( 11 MA 4837) 279B -279B
2003
Radioimmunotherapy with Iodine-131 anti-CD 20 chimeric monoclonal antigocy (rituximab) for relapsed or refractory indolent non-Hodgkin's lymphoma: results of an Australia phase II trial.
J Turner , R.J. Hicks , M.F. Leahy , J.F. Seymour
Radioimmunotherapy with Iodine-131 anti-CD 20 chimeric monoclonal antigocy (rituximab) for relapsed or refractory indolent non-Hodgkin's lymphoma: results of an Australia phase II trial.
2005
Evaluation of the Impact of Magnetic Resonance Imaging with Susceptibility-weighted Imaging for Screening and Surveillance of Radiation-induced Cavernomas in Long-term Survivors of Malignancy.
N. Goroncy , K. Wiltshire , M. Bressel , B.A. Campbell
Clinical Oncology
2021
CLINICAL OUTCOMES FROM VENETOCLAX BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMAS
K.L. Lewis , M. Dowling , K. Bavishi , A.K. Øvlisen
Hematological Oncology 37 535 -537
2019
CVP OR R‐CVP GIVEN AFTER INVOLVED‐FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I‐II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL
M.P. Macmanus , R. Fisher , D. Roos , P. O'Brien
Hematological Oncology 35 31 -31
3
2017
OUTCOMES WITH BRUTON TYROSINE KINASE INHIBITION IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AFTER PROGRESSION ON VENETOCLAX
M. Anderson , T.E. Lew , J.F. Seymour , A.W. Roberts
Hematological Oncology 35 236 -237
2017
HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB-3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY
J.F. Seymour , S. Opat , G. Cull , J. Trotman
Hematological Oncology 35 234 -235
4
2017
Stable Disease with Hematologic Improvement is Clinically Meaningful for Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine
A.C. Schuh , H. Döhner , J.F. Seymour , P. Turlure
Leukemia Research 55
4
2017
Impact of Gene Mutations on Survival with Azacitidine or Conventional Care Regimens (CCR) in Older Patients with Acute Myeloid Leukemia
L. Tang , A. Dolnik , K.J. MacBeth , H. Dombret
Leukemia Research 55
2017
Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study
J.F. Seymour , R. Buckstein , V. Santini , H. Döhner
Leukemia Research 55
1
2017
Azacitidine Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes
H. Döhner , P. Vyas , J.F. Seymour , V. Santini
Leukemia Research 55
2017
High Rate of Abscopal Regression of Follicular Lymphoma after Low Dose Involved-Site Radiation Therapy Detected by FDG-PET Scans
M.P. MacManus , M.S. Hofman , R. Hicks , B.A. Campbell
International Journal of Radiation Oncology Biology Physics 108 ( 3)
2020
Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.
Pierre Fenaux , G.J. Mufti , V. Santini , C. Finelli
Blood 110 ( 11) 817 -817
85
2007
Fludarabine and mitoxantrone: Effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders
J.F. Seymour , A.P. Grigg , J. Szer , R.M. Fox
Annals of Oncology 12 ( 10) 1455 -1460
30
2001
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study
H.M. Prince , M.J. Millward , D. Rischin , D. Blakey
Annals of Oncology 10 ( 4) 479 -481
17
1999
P-276 High doses of eltrombopag are well-tolerated in conjunction with azacitidine and demonstrate encouraging activity in patients with MDS and AML
M. Dickinson , K. Herbert , C. Sardjono , T. Le
Leukemia Research 37
1
2013
P-272 The combination of azacitidine and lenalidomide is deliverable without unexpected toxicity; interim safety results of the ALLG MDS4 randomised trial
M. Kenealy , J.F. Seymour , W. Benson , W. Stevenson
Leukemia Research 37
1
2013
13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL
M. Kenealy , W. Benson , W. Stevenson , R. Eek
Leukemia Research 39
5
2015